- Home
- AYRO vs SLRX Comparison
AYRO vs SLRX Comparison
Compare AYRO & SLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AYRO
- SLRX
- Stock Information
- Founded
- AYRO 2017
- SLRX N/A
- Country
- AYRO United States
- SLRX United States
- Employees
- AYRO N/A
- SLRX N/A
- Industry
- AYRO Telecommunications Equipment
- SLRX Biotechnology: Pharmaceutical Preparations
- Sector
- AYRO Consumer Discretionary
- SLRX Health Care
- Exchange
- AYRO Nasdaq
- SLRX Nasdaq
- Market Cap
- AYRO 3.7M
- SLRX 3.4M
- IPO Year
- AYRO N/A
- SLRX N/A
- Fundamental
- Price
- AYRO $7.08
- SLRX $5.77
- Analyst Decision
- AYRO
- SLRX
- Analyst Count
- AYRO 0
- SLRX 0
- Target Price
- AYRO N/A
- SLRX N/A
- AVG Volume (30 Days)
- AYRO 77.1K
- SLRX 432.7K
- Earning Date
- AYRO 08-14-2025
- SLRX 08-12-2025
- Dividend Yield
- AYRO N/A
- SLRX N/A
- EPS Growth
- AYRO N/A
- SLRX N/A
- EPS
- AYRO N/A
- SLRX N/A
- Revenue
- AYRO $5,426.00
- SLRX N/A
- Revenue This Year
- AYRO N/A
- SLRX N/A
- Revenue Next Year
- AYRO N/A
- SLRX N/A
- P/E Ratio
- AYRO N/A
- SLRX N/A
- Revenue Growth
- AYRO N/A
- SLRX N/A
- 52 Week Low
- AYRO $5.17
- SLRX $4.76
- 52 Week High
- AYRO $15.28
- SLRX $108.00
- Technical
- Relative Strength Index (RSI)
- AYRO 54.00
- SLRX 35.38
- Support Level
- AYRO $5.73
- SLRX $4.76
- Resistance Level
- AYRO $7.03
- SLRX $7.10
- Average True Range (ATR)
- AYRO 0.67
- SLRX 0.88
- MACD
- AYRO -0.01
- SLRX -0.19
- Stochastic Oscillator
- AYRO 61.14
- SLRX 21.54
About AYRO AYRO Inc.
AYRO Inc designs and manufactures compact, sustainable electric vehicles for closed campus mobility, low-speed urban and community transport, local on-demand and last-mile delivery, and government use. It operates as one reportable segment, focusing on the manufacturing and sales of environmentally-conscious, minimal-footprint EVs.
About SLRX Salarius Pharmaceuticals Inc.
Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.